| Date |
Subject |
Media |
| 2025-08-06 |
Daiken Biomedical’s June Revenue Soars Over 90% Year-on-Year with Seven Strategic Engines for Expansion
|
Daiken Biomedical announced that its consolidated revenue for June reached NT$175 million, a 93.35% increase compared to the same period last year. The company’s cumulative revenue from January to June grew 50.57% year-on-year. Concurrently, Daiken unveiled its “Seven Strategic Engines” international expansion blueprint, aiming to establish itself as Asia’s most promising health technology brand. |
| 2025-08-06 |
SYNMOSA Reports 5.7 Billion NTD Consolidated Revenue in June, Up 51.5% Year-on-Year
|
SYNMOSA saw its consolidated revenue reach 575 million NTD in June, representing a 51.5% increase compared to the same period last year and an 8% rise from May. The accumulated consolidated revenue for the first half of the year totaled 3.062 billion NTD, up 16.9% year-on-year. |
| 2025-08-06 |
Import Drug Tariffs at 200% Prompt Bora Pharmaceuticals and Lotus Pharmaceutical to Boost U.S. Manufacturing
|
U.S. President Donald Trump announced plans to impose a 200% tariff on imported drugs, allowing the industry a one-year grace period to relocate production lines to the United States. In response, Taiwan’s two major export-focused pharmaceutical companies, Bora Pharmaceuticals and Lotus Pharmaceutical, recently confirmed they have increased the proportion of drug production on their U.S. manufacturing lines. |
| 2025-08-06 |
Ever Fortune’s Hair Growth Cap Receives TFDA Medical Device Certification, Targets Hair Loss Treatment Market
|
Ever Fortune announced on the 9th that its subsidiary, Ever Wynn Technology, jointly developed the Reness Hair Growth Cap, which has received medical device certification from Taiwan’s TFDA. The company plans to apply next for U.S. FDA approval, aiming to enter the international market with its hair growth technology. |
| 2025-08-06 |
TaiHao Medical Inc. Launches AI Medical Devices in Southeast Asia
|
Taiwanese AI medical imaging leader TaiHao Medical Inc. announced multiple major international developments on July 10, demonstrating its technological strength and commercial progress in the global healthcare market. |
| 2025-08-06 |
Foresee Pharmaceuticals Reports June Revenue of NT$38.86 Million, Up 179% Month-on-Month; H1 Revenue Reaches NT$222 Million, Growing 12% Year-on-Year
|
Foresee Pharmaceuticals announced on the 9th that its consolidated revenue for June was approximately NT$38.86 million, representing a 179% increase from May and a 22% rise year-on-year. The cumulative consolidated revenue for the first half of this year reached about NT$222 million, marking a 12% year-on-year growth. |
| 2025-07-29 |
Tanvex’s June Consolidated Revenue Soars 997% Year-on-Year, Setting New Record; CDMO Revenue Surges
|
Tanvex-KY announced on the 8th that its preliminary consolidated revenue for June reached NT$26.56 million, up approximately 127% from the previous month and soaring 997.56% year-on-year, marking consecutive monthly growth and a new record for the same period. The preliminary consolidated revenue for Q2 totaled NT$46.82 million. Although exchange rate fluctuations caused a slight 6% decrease in NT dollar terms compared to the previous quarter, when measured in functional currency USD, Tanvex Biotech’s Q2 revenue reached about US$1.56 million, representing a 3% increase quarter-on-quarter. |
| 2025-07-29 |
CHLITINA HOLDING LIMITED’s Q2 Profit Boosted by RMB 18 Million Government Subsidy
|
CHLITINA HOLDING LIMITED (麗豐-KY) saw a significant profit boost in the second quarter, benefiting from a RMB 18 million (approximately NT$72.96 million) government subsidy recognized in its accounts. This subsidy contributed NT$0.88 to earnings per share (EPS), substantially higher than the Q1 EPS of NT$0.68. Coupled with a sales upturn in the Chinese mainland market following new product launches, analysts are optimistic about a strong quarterly profit performance, with potential for sustained momentum in the second half of the year. |
| 2025-07-29 |
Grape King Bio Maintains Full-Year Business Outlook
|
Grape King Bio reported a consolidated revenue of NT$4.82 billion for the first half of the year, a year-on-year decrease of 5.57%, due to weakened overall consumer spending. Revenue in June reached NT$880 million, representing a 6.79% increase from the previous month and remaining flat compared to the same period last year. The company anticipates that revenue in the second half will be boosted by the launch of new products, continuing its historical trend of stronger performance in the latter half of the year. All operational plans are proceeding as scheduled, and the company maintains its full-year growth target for consolidated performance. |
| 2025-07-29 |
HeXun Biosciences Reports NT$151 Million in Revenue for the First Half of the Year, Up 13.60% Year-on-Year
|
Driven by the strong momentum of its two core growth engines—CDMO/CMO clinical development and high-quality exosome raw materials—HeXun Biosciences posted revenue of NT$26.78 million in June. Cumulative revenue for the first half of the year reached NT$151 million, marking a 13.60% year-on-year increase. |
